Wild type p53 function in p53Y220C mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence
Sundar D, Yu Y, Katiyar SP, Putri JF, Dhanjal JK, Wang J, Sari AN, Kolettas E, Kaul SC, Wadhwa R
Journal of experimental & clinical cancer research : CR · 32 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio in vitro o de mecanismos (clasificado por nuestro filtro de IA)
- Estudiado en
- Células o muestras de laboratorio
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute of Advanced Industrial Science and Technology
- Universidad u hospital
- Indian Institute of Technology Delhi
Según 2 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2019-02-26 · J Exp Clin Cancer Res · vol. 38 · número 1 · pág. 103
- Editorial
- BioMed Central
- Citado
- 41 citas · más que el 95% de estudios similares · 5.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 61 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Phytochemicals and Medicinal Plants · Biological Research and Disease Studies · Pharmacology and Nanomedicine Research
- Palabras clave
- Mutant, Withaferin A, Wild type, Biology, Mutation, Mutagenesis, Withanolide, Gene, Biochemistry
- MeSH
- cell line, tumor, humans, plant extracts, antineoplastic agents, computational biology, apoptosis, molecular conformation, tumor suppressor protein p53, withanolides, molecular docking simulation
10 autores
- Durai Sundar🇮🇳Indian Institute of Technology Delhi
- Yue Yu🇯🇵National Institute of Advanced Industrial Science and Technology
- Shashank Prakash Katiyar🇮🇳Indian Institute of Technology Delhi
- Jayarani Fatimah Putri🇯🇵National Institute of Advanced Industrial Science and Technology
- Jaspreet Kaur Dhanjal🇮🇳Indian Institute of Technology Delhi
- Jia Wang🇯🇵National Institute of Advanced Industrial Science and Technology
- Anissa Nofita Sari🇯🇵National Institute of Advanced Industrial Science and Technology
- Evangelos Kolettas🇬🇷University of Ioannina
- Sunil C. Kaul🇯🇵 · autor de correspondenciaNational Institute of Advanced Industrial Science and Technology
- Renu Wadhwa🇯🇵 · autor de correspondenciaNational Institute of Advanced Industrial Science and Technology
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Tumor suppressor p53 protein is frequently mutated in a large majority of cancers. These mutations induce local or global changes in protein structure thereby affecting its binding to DNA. The structural differences between the wild type and mutant p53 thus provide an opportunity to selectively target mutated p53 harboring cancer cells. Restoration of wild type p53 activity in mutants using small molecules that can revert the structural changes have been considered for cancer therapeutics.
Methods
We used bioinformatics and molecular docking tools to investigate the structural changes between the wild type and mutant p53 proteins (p53V143A, p53R249S, p53R273H and p53Y220C) and explored the therapeutic potential of Withaferin A and Withanone for restoration of wild type p53 function in cancer cells. Cancer cells harboring the specific mutant p53 proteins were used for molecular assays to determine the mutant or wild type p53 functions.
Results
We found that p53V143A mutation does not show any significant structural changes and was also refractory to the binding of withanolides. p53R249S mutation critically disturbed the H-bond network and destabilized the DNA binding site. However, withanolides did not show any selective binding to either this mutant or other similar variants. p53Y220C mutation created a cavity near the site of mutation with local loss of hydrophobicity and water network, leading to functionally inactive conformation. Mutated structure could accommodate withanolides suggesting their conformational selectivity to target p53Y220C mutant. Using human cell lines containing specific p53 mutant proteins, we demonstrated that Withaferin A, Withanone and the extract rich in these withanolides caused restoration of wild type p53 function in mutant p53Y220C cells. This was associated with induction of p21WAF-1-mediated growth arrest/apoptosis.
Conclusion
The study suggested that withanolides may serve as highly potent anticancer compounds for treatment of cancers harboring a p53Y220C mutation.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.